SCYNEXIS, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent
SCYNEXIS, Inc. (SCYX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent of 0.00% for the 12-month period ending 2014-12-31, per its 8-K filed 2015-10-30.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization · last filed 2015-10-30
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent 12 month as first filed |
|---|---|---|
| 2014-12-31 | 0.00% 8-K · filed 2015-10-30 | |
| 2013-12-31 | -1.20% 8-K · filed 2015-10-30 | -1.30% 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |